Adaptimmune Therapeutics PLC (ADAPY) company profile

Adaptimmune is a commercial-stage biopharmaceutical company that develops and commercializes engineered T-cell immunotherapies to treat solid tumor cancers. The company utilizes autologous T-cell receptor and TRuC technology platforms to create personalized therapies from patients' own white blood cells. Its primary commercial product is TECELRA, an engineered T-cell therapy approved in the United States for adults with advanced or metastatic synovial sarcoma carrying specific genetic biomarkers. The company is also developing clinical and preclinical cell therapy candidates, including lete-cel for synovial sarcoma and liposarcoma, and uza-cel for head and neck cancer. Its therapies serve cancer patients with specific solid tumors, administered through specialized healthcare providers at medical centers.

The company maintains operational facilities in Philadelphia and Boston within the United States, as well as in the United Kingdom. In the United States, its commercial treatment network includes twenty authorized treatment centers. The text does not identify a specific corporate headquarters, though the organization conducts corporate functions and maintains sites across both countries.

Summary of the business section of Adaptimmune Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $17.00 per ADS.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2024, we had 506 employees.”